Use of C-C Chemokine Receptor Type 7 (CCR7) Inhibitors
AssigneeThe Schepens Eye Research Institute, Inc.
InventorsReza Dana, Sunil Chauhan, Shilpa Kodati, Daniel Saban
Life of this patent
Estimating the term…
Abstract
This application discloses ophthalmic formulations and methods for treating dry eye disease with a C-C chemokine receptor type 7 (CCR7) inhibitor.
Claims51
A method of treating ocular surface inflammatory disease comprising:
- identifying a subject who has been diagnosed with an ocular surface inflammatory disease;
- and
- administering to an ocular or adnexal tissue a composition comprising an effective amount of a C-C chemokine receptor type 7 (CCR7) inhibitor.
(canceled)
(canceled)
(canceled)
(canceled)
A method of reducing or preventing migration of antigen-presenting cells to lymphoid tissue comprising administering to ocular or adnexal tissue a composition comprising a CCR7 inhibitor.
A method of reducing or preventing the induction of pro-inflammatory T helper 1 (Th1) and T helper 17 (Th17)-mediated immunity in the draining lymphoid tissue of a subject with a resulting decrease in Th17-mediated immunity in an ocular or adnexal tissue in a subject, said method comprising administering to said ocular or adnexal tissue a composition comprising a CCR7 inhibitor in an amount effective to decrease a population of Th17 cells in said ocular or adnexal tissue, thereby reducing or preventing the induction of pro-inflammatory T helper 17 (Th17)-mediated immunity.
A method of preventing ocular surface inflammatory disease comprising:
- identifying a subject who is at risk for developing an ocular surface inflammatory disease;
- and
- administering to an ocular or adnexal tissue a composition comprising an effective amount of a C-C chemokine receptor type 7 (CCR7) inhibitor.
A composition comprising a C-C chemokine receptor type 7 (CCR7) inhibitor for treating an ocular surface inflammatory disease in a subject, wherein said composition is administered to an ocular or adnexal tissue of the subject.
Dependencies are inferred from the claim text.